Citius Oncology, Inc. Common Stock (CTOR)

• Market cap: $44.9M
• 1 day: -0.63%
• 5 days: -7.67%
• 1 month: -29.44%
• 3 months: -45.39%
• 6 months: -35.26%
• Year to date: -47.23%
• 1 year: -94.34%
• 5 years: -93.78%
• 10 years: -93.78%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

304% more capital invested

Capital invested by funds: $57K [Q3] → $230K (+$173K) [Q4]

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

57% more funds holding

Funds holding: 7 [Q3] → 11 (+4) [Q4]

0.22% more ownership

Funds ownership: 0.06% [Q3] → 0.28% (+0.22%) [Q4]